BEVERLY HILLS, Calif., April 30, 2014 /PRNewswire/ -- ImmunoClin Corporation (OTCBB: IMCL), is a U.S. healthcare company specializing in personalized medicine using proprietary immunological targets to develop prognostic tests, novel anti-infectious and anti-inflammatory therapies and innovative nutritional formulations. Today, the Company is pleased to announce the appointment of Berlin-based Dr. Marco Kaiser to its Scientific Advisory Board and looks forward to benefitting from Dr. Kaiser's expertise in molecular biology.
"Dr. Kaiser's proven scientific excellence coupled with his aptitude for applying his knowledge to the creation of practical inventions will undoubtedly add to the Company's insight and innovation," said Dorothy H. Bray, Ph.D., Director, President and CEO of ImmunoClin Corporation.
Dr. Kaiser is a key member of GenExpress GmbH, a known German molecular biology company. He studied at the Technical University Berlin in the field of medical biotechnology and completed his doctoral thesis in "Ultra sensitive multiplex diagnostics for emerging pathogens" at the Centre for Biological Threats and Specific Pathogens at the renowned Robert Koch Institute in Berlin, Germany. Dr. Kaiser also has a strong background in developing technologies for use in virology and dermatological research, and has authored numerous scientific publications and oral presentations.
"I have worked for years in the development and implementation of diagnostic tools e.g. for pathogen detection, with emphasis in molecular biology and clinical diagnosis. I look forward to working with ImmunoClin to bring the Company's intellectual property portfolio to clinical application," stated Dr. Kaiser.
About ImmunoClin Corporation
ImmunoClin Corporation is a healthcare company with European headquarters in London, United Kingdom and laboratories in central Paris, France. ImmunoClin concentrates its innovation on developing personalized and preventive strategies to fight inflammatory conditions that are the underlying cause of pathologies in multiple conditions affecting the majority of the human population: infections, cancer, cardiovascular disease, and dementia, including Alzheimer's disease.
Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of technologies, pharmaceuticals, and food products. ImmunoClin Corporation does not undertake any duty nor does it intend to update the results of these forward-looking statements.
Dr. Dorothy Bray, Director, President & CEO
J. Scott Munro, CFO
Cell: +1 778-987-4308
SOURCE ImmunoClin Corporation